Endocan and Endothelial Dysfunction

Angiology

Volumn 66, Issue 5, 2015, Pages 488-489

  Aparci, Mustafa ^a   Isilak, Zafer ^b   Uz, Omer ^b   Yalcin, Murat ^b   Kucuk, Ugur ^b  

^a TURKISH AIR FORCE ACADEMY   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; AUTACOID; PROTEOGLYCAN; TUMOR PROTEIN;

CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; DISEASE MARKER; ENDOCAN; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; LETTER; OXIDATIVE STRESS; PSORIASIS VULGARIS; BLOOD; FEMALE; MALE;

FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; NEOPLASM PROTEINS; PROTEOGLYCANS;

EID: 84928031298     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714568791     Document Type: Letter

References (12)

1. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan - a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014 ; 65 (9). 773-777
2. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006 ; 31 (4). 386-393
3. Lane HA, Smith JC, Davies JS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006 ; 2 (1). 19-30
4. Whayne TF. Endocan in hypertension and cardiovascular disease. Angiology. 2014 ; 65 (9). 757-759
5. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014 ; 86 (6). 1213-1220
6. Karaman M, Balta S, Ay SA, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013 ; 35 (7). 516-522
7. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014 ; 229 (5). 620-630
8. Su Y-H, Shu K-H, Hu C-P, et al. Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014 ; 46 (2). 323-327
9. Tok D, Ekiz F, Basar O, Coban S, Ozturk G. Serum endocan levels in patients with chronic liver disease. Int J Clin Exp Med. 2014 ; 7 (7). 1802-1807
10. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014 ; 70 (2). 291-296
11. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013 ; 169 (5). 1066-1070
12. Fici F, Celik T, Balta S, et al. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension. J Cardiovasc Pharmacol. 2013 ; 62 (4). 388-393